Who Pays My Doctor?

Healthcare provider profile · identity verified

Diego Ruiz Dasilva, MD

Allopathic & Osteopathic Physicians|Dermatology · VIRGINIA BEACH, VA · NPI 1912499047

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Diego Ruiz Dasilva, MD received $654,774.76 in general payments during 2025 across 786 reported records.

Galderma Laboratories, L.P. accounted for 19.1% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 27 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Adbry, Rinvoq, Zoryve.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rinvoq by this doctor in 2024.

Arcutis Biotherapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Zoryve as an associated drug or biological on 56906 records involving 10745 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Zoryve by this doctor in 2024.

Kowa Pharmaceuticals America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZORYVE as an associated drug or biological on 22731 records involving 10996 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Zoryve by this doctor in 2024.

LEO Pharma Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ADBRY as an associated drug or biological on 37730 records involving 9327 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Adbry by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$654,774.76

786 reported records · 25 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
Galderma Laboratories, L.P. Unresolved — no canonical attribution shown $125,079.9419.1%1442025
GENZYME CORPORATION Unresolved — no canonical attribution shown $124,949.7119.1%802025
PFIZER INC. Unresolved — no canonical attribution shown $79,056.1012.1%602025
UCB, Inc. Unresolved — no canonical attribution shown $73,262.1911.2%822025
ABBVIE INC. Unresolved — no canonical attribution shown $73,120.1911.2%1002025
LEO Pharma Inc. Unresolved — no canonical attribution shown $71,901.1811.0%1022025
Organon LLC Unresolved — no canonical attribution shown $39,786.296.1%412025
Arcutis Biotherapeutics, Inc. Unresolved — no canonical attribution shown $38,105.025.8%422025
Incyte Corporation Unresolved — no canonical attribution shown $9,645.581.5%252025
Verrica Pharmaceuticals Inc. Unresolved — no canonical attribution shown $7,362.291.1%72025
Novartis Pharmaceuticals Corporation Unresolved — no canonical attribution shown $4,168.950.6%162025
Kowa Pharmaceuticals America, Inc. Unresolved — no canonical attribution shown $3,699.980.6%32025
Janssen Biotech, Inc. Unresolved — no canonical attribution shown $3,223.030.5%212025
Regeneron Healthcare Solutions, Inc. Unresolved — no canonical attribution shown $583.910.1%192025
Amgen Inc. Unresolved — no canonical attribution shown $225.950.0%112025
E.R. Squibb & Sons, L.L.C. Unresolved — no canonical attribution shown $179.890.0%162025
SUN PHARMACEUTICAL INDUSTRIES INC. Unresolved — no canonical attribution shown $119.630.0%42025
SANOFI-AVENTIS U.S. LLC Unresolved — no canonical attribution shown $72.000.0%12025
Lilly USA, LLC Unresolved — no canonical attribution shown $62.160.0%42025
ConvaTec Inc. Unresolved — no canonical attribution shown $49.310.0%22025
LNHC, Inc Unresolved — no canonical attribution shown $40.730.0%22025
SpringWorks Therapeutics, Inc. Unresolved — no canonical attribution shown $27.950.0%12025
Boehringer Ingelheim Pharmaceuticals, Inc. Unresolved — no canonical attribution shown $27.530.0%12025
REVANCE THERAPEUTICS, INC. Unresolved — no canonical attribution shown $15.130.0%12025
Janssen Scientific Affairs, LLC Unresolved — no canonical attribution shown $10.120.0%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program$416,208.72107
Consulting Fee$137,634.2470
Travel and Lodging$47,286.20119
Honoraria$36,600.0017
Food and Beverage$16,750.00467
Education$295.606

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
DUPIXENT
Normalized: dupixent		 Biological GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc., SANOFI-AVENTIS U.S. LLC $125,536.01 99 2025
Source payment records
NEMLUVIO
Normalized: nemluvio		 Drug Galderma Laboratories, L.P. $122,161.79 127 2025
Source payment records
Bimzelx
Normalized: bimzelx		 Biological UCB, Inc. $73,178.13 79 2025
Source payment records
RINVOQ
Normalized: rinvoq		 Biological ABBVIE INC. $58,668.29 67 2025
Source payment records
CIBINQO
Normalized: cibinqo		 Drug PFIZER INC. $48,860.03 44 2025
Source payment records
ADBRY
Normalized: adbry		 Biological LEO Pharma Inc. $44,131.24 59 2025
Source payment records
ZORYVE
Normalized: zoryve		 Drug Arcutis Biotherapeutics, Inc., Kowa Pharmaceuticals America, Inc. $41,805.00 45 2025
Source payment records
VTAMA
Normalized: vtama		 Drug Organon LLC $39,786.29 41 2025
Source payment records
LITFULO
Normalized: litfulo		 Drug PFIZER INC. $30,537.98 28 2025
Source payment records
ANZUPGO
Normalized: anzupgo		 Drug LEO Pharma Inc. $30,259.75 48 2025
Source payment records
SKYRIZI
Normalized: skyrizi		 Biological ABBVIE INC. $12,946.00 29 2025
Source payment records
OPZELURA
Normalized: opzelura		 Drug Incyte Corporation $9,645.58 25 2025
Source payment records
YCANTH
Normalized: ycanth		 Drug Verrica Pharmaceuticals Inc. $7,362.29 7 2025
Source payment records
TREMFYA
Normalized: tremfya		 Drug Janssen Biotech, Inc., Janssen Scientific Affairs, LLC $3,233.15 22 2025
Source payment records
OTEZLA
Normalized: otezla		 Drug Amgen Inc. $225.95 11 2025
Source payment records
Sotyktu
Normalized: sotyktu		 Drug E.R. Squibb & Sons, L.L.C. $179.89 16 2025
Source payment records
Rhapsido
Normalized: rhapsido		 Drug Novartis Pharmaceuticals Corporation $164.93 4 2025
Source payment records
ILUMYA
Normalized: ilumya		 Biological SUN PHARMACEUTICAL INDUSTRIES INC. $119.63 4 2025
Source payment records
EBGLYSS
Normalized: ebglyss		 Drug Lilly USA, LLC $62.16 4 2025
Source payment records
SPEVIGO
Normalized: spevigo		 Biological, Drug Boehringer Ingelheim Pharmaceuticals, Inc., LEO Pharma Inc. $58.23 2 2025
Source payment records
BOTOX
Normalized: botox		 Biological ABBVIE INC. $55.90 2 2025
Source payment records
INNOVAMATRIX AC
Normalized: innovamatrix ac		 Device ConvaTec Inc. $49.31 2 2025
Source payment records
COSENTYX
Normalized: cosentyx		 Drug Novartis Pharmaceuticals Corporation $46.37 3 2025
Source payment records
ZELSUVMI
Normalized: zelsuvmi		 Drug LNHC, Inc $40.73 2 2025
Source payment records
TALTZ
Normalized: taltz		 Drug Lilly USA, LLC $29.17 2 2025
Source payment records
GOMEKLI
Normalized: gomekli		 Drug SpringWorks Therapeutics, Inc. $27.95 1 2025
Source payment records
DAXXIFY
Normalized: daxxify		 Drug REVANCE THERAPEUTICS, INC. $15.13 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments productPayment yearPart D brandPart D yearClaimsMatch methodSource
ADBRY
adbry		 2025 Adbry 2024 15
Beneficiary count suppressed		 exact normalized Medicare Part D
RINVOQ
rinvoq		 2025 Rinvoq 2024 27
Beneficiary count suppressed		 exact normalized Medicare Part D
ZORYVE
zoryve		 2025 Zoryve 2024 20 exact normalized Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying companyPayment yearDrug reported by same entityOpen Payments evidencePart DClaimsBeneficiaries
ABBVIE INC.
Exact reporting entity; no affiliate inference		 2025 RINVOQ
open payments reported associated product		 CMS Open Payments — General Payments
279238 supporting records · 34343 recipient NPIs · example record 1201352600 		Rinvoq · 2024
Exact normalized brand match · 1 Part D row		 27 suppressed by CMS
Arcutis Biotherapeutics, Inc.
Exact reporting entity; no affiliate inference		 2025 Zoryve
open payments reported associated product		 CMS Open Payments — General Payments
56906 supporting records · 10745 recipient NPIs · example record 1252324094 		Zoryve · 2024
Exact normalized brand match · 1 Part D row		 20 11
Kowa Pharmaceuticals America, Inc.
Exact reporting entity; no affiliate inference		 2025 ZORYVE
open payments reported associated product		 CMS Open Payments — General Payments
22731 supporting records · 10996 recipient NPIs · example record 1243071225 		Zoryve · 2024
Exact normalized brand match · 1 Part D row		 20 11
LEO Pharma Inc.
Exact reporting entity; no affiliate inference		 2025 ADBRY
open payments reported associated product		 CMS Open Payments — General Payments
37730 supporting records · 9327 recipient NPIs · example record 1251989155 		Adbry · 2024
Exact normalized brand match · 1 Part D row		 15 suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
Clobetasol PropionateClobetasol Propionate271128
Triamcinolone AcetonideTriamcinolone Acetonide200141
KetoconazoleKetoconazole15864
Doxycycline HyclateDoxycycline Hyclate7143
TretinoinTretinoin5931
GabapentinGabapentin5413
MupirocinMupirocin5439
Doxepin HclDoxepin Hcl51suppressed
DutasterideDutasteride5121
Fluocinolone AcetonideFluocinolone/Shower Cap3616
Dupixent PenDupilumab35suppressed
Ammonium LactateAmmonium Lactate3323
HydrocortisoneHydrocortisone3317
RinvoqUpadacitinib27suppressed
FluconazoleFluconazole2518
MinoxidilMinoxidil22suppressed
Terbinafine HclTerbinafine Hcl2016
ValacyclovirValacyclovir Hcl2015
ZoryveRoflumilast2011
Hydroxyzine HclHydroxyzine Hcl19suppressed
Skyrizi PenRisankizumab-Rzaa19suppressed
TacrolimusTacrolimus17suppressed
AdbryTralokinumab-Ldrm15suppressed
Clindamycin-Benzoyl PeroxideClindamycin Phos/Benzoyl Perox15suppressed
DesonideDesonide15suppressed
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc12suppressed
Cosentyx Unoready PenSecukinumab12suppressed
MetronidazoleMetronidazole12suppressed
Silver SulfadiazineSilver Sulfadiazine12suppressed
SpironolactoneSpironolactone12suppressed
Clindamycin PhosphateClindamycin Phosphate11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $654,774.76 · 786 records Galderma Laboratories, L.P. ADBRY, ANZUPGO, BOTOX, Bimzelx, CIBINQO, COSENTYX, DAXXIFY, DUPIXENT, EBGLYSS, GOMEKLI, ILUMYA, INNOVAMATRIX AC, LITFULO, NEMLUVIO, OPZELURA, OTEZLA, RINVOQ, Rhapsido, SKYRIZI, SPEVIGO, Sotyktu, TALTZ, TREMFYA, VTAMA, YCANTH, ZELSUVMI, ZORYVE 4 —
2024 — — — — Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error